Abstracts
Showing 852 abstracts.
Citation
Adriana Weinberg, M.D., Mona Rigaud, M.D., Petronella Muresan, M.S., Philip LaRussa, M.D., Patrick Jean-Philippe, M.D., Jennifer S. Read, M.D., M.P.H., M.S., DTM&H, William Borkowsky, M.D. T-cell phenotypes and responses to vaccines in severely immunocompromised HIV-infected children initiating HAART in PACTG 1006. Presented at: 14th Conference on Retroviruses and Opportunistic Infections.Conference
14th Conference on Retroviruses and Opportunistic Infections
Study
P1006
Citation
K Rough, GR Seage III, PL Williams, S Hernandez-Diaz, Y Huo, EG Chadwick, RM Hoffman, E Barr, ED Shapiro, K Patel. TDF/FTC in pregnancy shows no increase in adverse infant birth outcomes in US cohorts. Presented at: CROI 2018.Conference
CROI 2018
Study
P1025
Citation
K Rough, GR Seage III, PL Williams, S Hernandez-Diaz, Y Huo, EG Chadwick, RM Hoffman, E Barr, ED Shapiro, K Patel. TDF/FTC in pregnancy shows no increase in adverse infant birth outcomes in US cohorts. Presented at: CROI 2017; 2017 Feb 16.Conference
CROI 2017
Citation
JD Momper, B Best, J Wang, A Stek, TR Cressey, S Burchett, R Kreitchmann, DE Shapiro, E Smith, N Chakhtoura, EV Capparelli, M Mirochnick, IMPAACT P1026s Protocol team. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. Presented at: CROI 2018.Conference
CROI 2018
Study
P1026S
Citation
Tenofovir Disoproxil Fumarate (TDF) Pharmacokinetics (PK) with Daily Dosing in the First Week of Life (HPTN 057). Presented at: XIX International AIDS Conference.Conference
XIX International AIDS Conference
Citation
Tenofovir Disoproxil Fumarate (TDF) Pharmacokinetics (PK) with Increased Doses in HIV-1 Infected Pregnant Women and their Newborns (HPTN 057).Citation
PM Murnane, P Bacchetti, JS Currier, S Brummel, H Okochi, N Phung, K Kuncze, R Hoffman, T Nematadzira, D Soko, M Owor, F Saidi, PM Flynn, MG Fowler, M Gandhi. Tenofovir hair levels rise over the postpartum period and highly predict viral loads. Presented at: CROI 2019; 2019 Mar 07.Conference
CROI 2019
Study
1077BF
Citation
Jennifer R. King, Pharm.D., Ram Yogev, M.D., Andrew A. Wiznia, M.D., Bobbie L. Graham, B.S., Vincent J. Carey, Ph.D., Paula Britto, M.S., Patrick Jean-Philippe, M.D., Eric K. Stets, B.S., Edward P. Acosta, Pharm.D. Tenofovir pharmacokinetics across three tenofovir-based antiretroviral regimens in HIV-infected children and adolescents. Presented at: 10th Int'l Workshop on Clinical Pharmacology of HIV Therapy.Conference
10th Int'l Workshop on Clinical Pharmacology of HIV Therapy
Citation
Sandra K. Burchett, M.D., M.S., Brookie M. Best, Pharm.D., Mark Mirochnick, M.D., ChengCheng Hu, Ph.D., Edmund Capparelli, Pharm.D., Diane Holland, M.Phil., Elizabeth (Betsy) Smith, M.D., Jennifer S. Read, M.D., M.P.H., M.S., DTM&H, Alice M. Stek, M.D. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Presented at: 14th Conference on Retroviruses and Opportunistic Infections.Conference
14th Conference on Retroviruses and Opportunistic Infections
Study
P1026S